Evidence map›Paper›PMID 37033394›Full record

ArticleInternational journal of clinical and experimental pathology2023

Comprehensive diagnosis and treatment of ductal carcinoma of the submandibular gland: case report and literature review.

Feng Liu, Li Fan, Lifang Lu, Hongyi Guo, Jie Nan, Fei Han

Open access · greenAbstract readCase Reports
In one paragraph

Article in International journal of clinical and experimental pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Feng LiuDepartment of Head and Neck Surgery, Shanxi Provincial Cancer Hospital/Shanxi Hospital, Cancer Hospital of Chinese Academy of Medical Sciences Taiyuan 030013, Shanxi, China.
Li FanDepartment of Head and Neck Surgery, Shanxi Provincial Cancer Hospital/Shanxi Hospital, Cancer Hospital of Chinese Academy of Medical Sciences Taiyuan 030013, Shanxi, China.
Lifang LuDepartment of Head and Neck Surgery, Shanxi Provincial Cancer Hospital/Shanxi Hospital, Cancer Hospital of Chinese Academy of Medical Sciences Taiyuan 030013, Shanxi, China.
Hongyi GuoDepartment of Head and Neck Surgery, Shanxi Provincial Cancer Hospital/Shanxi Hospital, Cancer Hospital of Chinese Academy of Medical Sciences Taiyuan 030013, Shanxi, China.
Jie NanDepartment of Head and Neck Surgery, Shanxi Provincial Cancer Hospital/Shanxi Hospital, Cancer Hospital of Chinese Academy of Medical Sciences Taiyuan 030013, Shanxi, China.
Fei HanDepartment of Head and Neck Surgery, Shanxi Provincial Cancer Hospital/Shanxi Hospital, Cancer Hospital of Chinese Academy of Medical Sciences Taiyuan 030013, Shanxi, China.
Shanxi Provincial Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salivary duct carcinoma (SDC) is a rare malignant tumor of the salivary gland and is most commonly found in the parotid gland, followed by the submandibular gland. Due to its rarity, there is no consensus on its treatment. Surgical resection is currently the only curative treatment. Considering its high degree of malignancy, extensive tumor resection and postoperative adjuvant radiotherapy are recommended. We report a rare case of SDC of the submandibular gland. A 62-year-old man presented to our hospital with complaints of swelling in the right submaxillary area for 4 months, rapidly growing, with pain for 10 days. After admission, fine needle aspiration (FNA) revealed right submandibular gland ductal carcinoma. Considering its aggressiveness, large size, and invasion of parapharyngeal and oral floor soft tissues, the patient received two cycles of neoadjuvant chemotherapy followed by extended surgical resection. Postoperatively, the patient received four cycles of concurrent chemoradiotherapy, followed by afatinib targeted therapy. No recurrence or metastasis was observed in a 45-month follow-up. Thus we present a comprehensive treatment for salivary duct carcinoma combining neoadjuvant chemotherapy with surgery, postoperative concurrent radiotherapy, and chemotherapy followed by afatinib targeted therapy.

Indexed as

ductal carcinomasalivary glandsalivary gland malignancySubmaxillary gland

Identifiers

PMID37033394
PMCPMC10076972
OpenAlexW4363645565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.